Abstract
Obesity represents a major problem in the western world today. Dietary restriction continues to play a major part in the treatment and management of this condition, and its importance lies not only in obtaining a weight loss but in maintaining the new weight once it is arrived at. Thus the total aim is the re-education of the individual's eating habits.
Recently, research work has been conducted on a new drug called fenfluramine which does not produce sympathomimetic side effects, but nevertheless produces an excellent effect for the reduction of weight both by anorectic activity and peripheral metabolic activity.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- HVIDT S., KJELDSEN K. Malabsorption induced by small doses of neomycin sulphate. Acta Med Scand. 1963 Jun;173:699–705. doi: 10.1111/j.0954-6820.1963.tb17455.x. [DOI] [PubMed] [Google Scholar]
- Hill R. C., Turner P. Fenfluramine and critical flicker frequency. J Pharm Pharmacol. 1967 May;19(5):337–338. doi: 10.1111/j.2042-7158.1967.tb08098.x. [DOI] [PubMed] [Google Scholar]
- Munro J. F., Seaton D. A., Duncan L. J. Treatment of refractory obesity with fenfluramine. Br Med J. 1966 Sep 10;2(5514):624–625. doi: 10.1136/bmj.2.5514.624. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Traherne J. B. A clinical trial of fenfluramine. Practitioner. 1965 Nov;195(169):677–680. [PubMed] [Google Scholar]